E

    Evogene (EVGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.54
    -0.01 (-2.38%)

    Market Cap: $8.68M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    42%(16/38)
    Avg Surprise
    -96.71%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.27
    Range$-0.27 - $-0.27
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$-0.27+0.0%
    30d ago$-0.27+0.0%
    7d ago$-0.27+0.0%
    Current$-0.27
    Revenue Consensus
    $400000
    Range$400000 - $400000
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.89
    Range$-0.89 - $-0.89
    1 analysts
    Revenue Consensus
    $409000
    Range$409000 - $409000
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.89---
    Sep 26EST
    		-$-0.27---
    Jun 26
    Reported Aug 18
    		$-0.13N/A+51.85%Beat+74.0%
    Mar 26
    Reported May 20
    		$-0.61$-0.27-125.93%Miss-60.5%
    Dec 25
    Reported Mar 5
    		$-0.62$-0.41-50.59%Miss-1129.0%
    Sep 25
    Reported Nov 20
    		$-0.46$-0.41-12.20%Miss+64.9%
    Jun 25
    Reported Aug 28
    		$-0.50$-0.63+20.63%Beat+52.8%
    Mar 25
    Reported May 21
    		$-0.38$-0.50+24.00%Beat+52.5%
    Dec 24
    Reported Mar 6
    		$0.06N/A+108.28%Beat+104.6%
    Sep 24
    Reported Nov 21
    		$-1.31$-1.01-29.70%Miss-63.7%
    Jun 24
    Reported Aug 22
    		$-1.06$-1.20+11.67%Beat+37.6%
    Mar 24
    Reported May 23
    		$-0.80$-0.90+11.11%Beat+46.7%
    Dec 23
    Reported Mar 7
    		$-1.30$-1.40+7.14%Beat-1757.1%
    Sep 23
    Reported Nov 15
    		$-0.80$-1.57+49.04%Beat+50.0%
    Jun 23
    Reported Aug 17
    		$-1.70$-1.75+2.86%Beat+19.0%
    Mar 23
    Reported May 18
    		$-1.50$-1.60+6.25%Beat+25.0%
    Dec 22
    Reported Mar 9
    		$-0.07N/A+65.00%Beat+96.1%
    Sep 22
    Reported Nov 17
    		$-1.60$-1.97+18.78%Beat+15.8%
    Jun 22
    Reported Aug 31
    		$-2.10$-1.90-10.53%Miss-40.0%
    Mar 22
    Reported May 26
    		$-2.00$-1.80-11.11%Miss-17.6%
    Dec 21
    Reported Mar 10
    		$-1.80$-2.00+10.00%Beat+28.0%
    Sep 21
    Reported Nov 17
    		$-1.90$-1.77-7.34%Miss-1017.6%
    Jun 21
    Reported Aug 11
    		$-1.50$-1.65+9.09%Beat-837.5%
    Mar 21
    Reported May 26
    		$-1.70$-1.80+5.56%Beat-608.3%
    Dec 20
    Reported Mar 3
    		$-2.50$-1.70-47.06%Miss-941.7%
    Sep 20
    Reported Nov 18
    		$-0.17N/A+90.00%Beat-6.3%
    Jun 20
    Reported Aug 5
    		$-0.16N/AN/ABeat+0.0%
    Mar 20
    Reported May 26
    		$-0.24N/AN/ABeat-60.0%
    Dec 19
    Reported Mar 4
    		$-0.24$0.34-170.59%Miss-4.3%
    Sep 19
    Reported Nov 13
    		$-0.16$0.18-188.89%Miss+91.6%
    Jun 19
    Reported Jul 31
    		$-0.16$0.19-184.21%Miss+91.6%
    Mar 19
    Reported May 28
    		$-0.15$0.30-150.00%Miss+92.9%
    Dec 18
    Reported Mar 13
    		$-0.23$-0.19-21.05%Miss+90.4%
    Sep 18
    Reported Nov 14
    		$-1.90$-0.18-955.56%Miss+5.0%
    Jun 18
    Reported Aug 8
    		$-1.90$-0.19-900.00%Miss-5.6%
    Mar 18
    Reported May 29
    		$-2.10$-0.19-1005.26%Miss-10.5%
    Dec 17
    Reported Feb 28
    		$-2.40$-2.10-14.29%Miss+7.7%
    Sep 17
    Reported Nov 22
    		$-2.00$-1.70-17.65%Miss+0.0%
    Jun 17
    Reported Aug 10
    		$-1.80$-1.40-28.57%Miss-
    Mar 17
    Reported May 17
    		$-1.90$-1.80-5.56%Miss-
    Dec 16
    Reported Feb 27
    		$-2.60$-1.80-44.44%Miss-
    Sep 16
    Reported Nov 21
    		$-2.00$-0.70-185.71%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.30EV/EBITDA-0.81x
    Price/FCF-0.57xFCF Yield-176.68%
    Profitability
    Profit Margin0.00%Operating Margin-739.00%
    ROE-182.70%ROIC513.35%
    Financial Health
    Debt/Equity-0.20xInterest Coverage-2.77x
    Current Ratio3.57xQuick Ratio3.54x
    Trading Statistics
    Beta0.68Avg Volume636.13K
    52-Week High$1.5052-Week Low$0.37

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.56
    SMA 20$0.60
    SMA 50$0.53
    SMA 200$0.81
    EMA 10$0.56
    EMA 20$0.57
    EMA 50$0.57
    EMA 200$0.78

    MACD

    Line: -0.00Signal: 0.00Hist: -0.01

    ADX

    ADX: 13.7+DI: 18.1-DI: 21.9

    Aroon & PSAR

    Aroon Up40.0
    Aroon Down20.0
    PSAR$0.72

    Bollinger Bands

    Upper Band$0.69
    Lower Band$0.50
    %B Position3338%(Upper)
    Band Width0.20

    RSI (14-Day)

    Neutral
    45.8

    Momentum Oscillators

    Stoch %K12.3
    Stoch %D9.6
    Williams %R-85.0
    ROC (10d)-4.2%
    Momentum-0.02
    CCI (20d)-100.2
    MFI (14d)17.9

    Volatility Measures

    ATR (14d)$0.06(10.7%)
    StdDev (20d)0.05
    Hist Vol127.5%(High)

    Volume Flow

    VWAP$0.53
    OBV105.6M
    AD Line60.3M
    CMF (20d)-0.251

    Volume Metrics

    Avg Vol (20d)656.0K
    Vol Ratio0.2x(Low)
    VWMA (20d)$0.62

    Pivot Points

    R3$0.58
    R2$0.57
    R1$0.56
    Pivot Point$0.55
    S1$0.54
    S2$0.53
    S3$0.51

    Advanced Oscillators

    TSI-1.84
    Ultimate Osc49.4
    KST102.27

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$347,000$334,000$314,000$312,000$884,000$2.44M$1.61M$1.74M$605,000$4.19M$578,000$3.77M
    Cost of Revenue$355,000$130,000$2.28M$157,000$136,000$1.61M$755,000$1.04M$336,000$310,000$398,000$511,000
    Gross Profit$-8,000$204,000$-1,970,000$155,000$748,000$830,000$856,000$698,000$269,000$3.88M$180,000$3.26M
    Operating Expenses$2.43M$3.35M$3.24M$2.88M$3.82M$4.96M$5.42M$6.62M$4.90M$7.97M$7.81M$7.44M
    R&D$1.23M$1.84M$1.83M$1.38M$2.32M$3.21M$3.40M$3.31M$2.88M$4.80M$5.54M$5.06M
    SG&A$0$1.16M$2.19M$1.13M$1.09M$1.29M$4.54M$2.79M$1.42M$1.65M$3.83M$1.53M
    Operating Income$-2,441,000$-3,150,000$-5,212,000$-2,724,000$-3,071,000$-4,126,000$-4,567,000$-5,920,000$-4,629,000$-4,086,000$-7,628,000$-4,183,000
    Interest Income$0$1.17M$1.93M$465,000$235,000$1.60M$1.86M$2.15M$260,000$407,000$120,000$429,000
    Interest Expense$168,000$3.88M$350,000$453,000$628,000$464,000$144,000$2.89M$97,000$166,000$71,000$109,000
    Income Before Tax$-1,591,000$-5,906,000$-5,338,000$-2,728,000$-3,528,000$-2,989,000$2,000$-6,747,000$-4,552,000$-3,845,000$-7,341,000$-3,863,000
    Income Tax Expense$0$4,000$0$1,000$1,000$0$7,000$1,000$1,000$425,000$-4,000$-5,000
    Net Income$-1,768,000$-5,870,000$-5,309,000$3.87M$-4,462,000$-2,587,000$427,000$-7,630,000$-5,419,000$-3,863,000$-6,601,000$-3,984,000
    EBITDA$-2,292,000$-1,820,000$-6,459,000$-1,994,000$-2,610,000$-1,946,000$-2,540,000$-3,649,000$-4,125,000$-3,008,000$-7,457,000$-3,093,000
    EBIT$-2,441,000$-2,022,000$-6,722,000$-2,275,000$-2,900,000$-2,525,000$-3,133,000$-3,858,000$-4,455,000$-3,679,000$-8,120,000$-3,754,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EVGN

    News

    L.I.A. Pure Capital Acquires 19.35% Activist Stake in Evogene (NASDAQ: EVGN)

    L.I.A. Pure Capital has acquired a 19.35% activist stake in Evogene (NASDAQ: EVGN), holding 3,057,488 ordinary shares. Alongside Invest Pro, L.I.A. Pure Capital is urging shareholders to support their board nominees due to concerns about Evogene's performance, governance, and board structure. Both investment firms have disclosed their beneficial ownership and are actively campaigning for changes at the upcoming annual meeting.

    Kalkine Media•9/1/26•
    Somewhat-Bearish

    L.I.A. Pure Capital Takes 19.35% Activist Stake in Evogene (NASDAQ: EVGN), Pushes for Board Changes

    L.I.A. Pure Capital has acquired a 19.35% activist stake in Evogene (NASDAQ: EVGN), holding 3,057,488 ordinary shares. Alongside Invest Pro Shukai Hon Ltd., the firm is actively urging shareholders to support their board nominees due to concerns about Evogene's operational performance, governance, and board composition. This move aims to influence the upcoming annual meeting's board election.

    Kalkine Media•9/1/26•
    Somewhat-Bearish

    Evogene Updates U.S. Investors With New August 2026 Presentation

    Evogene, an Israel-based biotechnology company specializing in computational biology, has filed an updated investor presentation (Form 6-K) with the SEC on August 27, 2026. This filing aims to enhance transparency and engagement with U.S. investors, highlighting the company's focus on high-value therapeutic areas like oncology and its strategic direction in global healthcare markets. Despite an analyst rating of "Buy" with a $2.15 price target, TipRanks' AI Analyst, Spark, assesses EVGN as "Neutral" due to weak financial performance and mixed technicals.

    TipRanks•8/27/26•
    Bearish

    How Evogene is Putting AI Agents to Work on Small-Molecule Discovery

    Evogene Ltd. is using AI agents, specifically its ChemPass AI engine, to accelerate the discovery and optimization of small molecules for both pharmaceuticals and agriculture. This technology aims to streamline the drug discovery process by integrating efficacy, selectivity, safety, and manufacturability considerations early on, significantly reducing the time and cost involved. Evogene is pursuing a dual strategy, advancing its internal drug discovery programs while also engaging in partnerships to apply its AI platform to a wide range of therapeutic areas and crop protection needs.

    Technology Org•8/24/26•
    Bullish

    Evogene Ltd (EVGN) Stock News Today

    This article provides the latest news and stock information for Evogene Ltd (EVGN), a biotechnology and medical research company. It highlights the company's recent Q2 2026 earnings call, where a narrower loss was reported and its ChemPass AI expanded. The page also includes real-time stock data and links to financial and analytical sections.

    TradingKey•8/23/26•
    Somewhat-Bullish

    Frequently Asked Questions About EVGN

    Does EVGN pay dividends?
    Evogene (EVGN) does not currently pay a regular dividend.
    What is EVGN's market cap?
    Evogene (EVGN) has a market capitalization of $8.68M with a current stock price of $0.54.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In